Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698179 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL5413813 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL24324236 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL3029758 | 0.90 | CTSK (0.55) | CTRB1CTSBACE2CTSKCTSL | |
| SCHEMBL8478010 | 0.90 | CTRB1 (0.54) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL2582361 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL2577831 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL4908808 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL14395196 | 0.89 | BACE1 (0.51) | BCHEBACE1SLC6A11 | |
| SCHEMBL2601900 | 0.88 | BACE1 (0.62) | TRPM8CTRB1CTSBBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032889-A1 | Process for producing crystal of benzenesulfonamide derivative, and novel crystal of intermediate therefor and process for producing the same | AJINOMOTO CO., INC (JP) | 2005-02-10 | — | — | US | claimed |
| EP-1466896-A1 | PROCESS FOR PRODUCING CRYSTAL OF BENZENESULFONAMIDE DERIVATIVE, AND NOVEL CRYSTAL OF INTERMEDIATE THEREFOR AND PROCESS FOR PRODUCING THE SAME | Ajinomoto Co., Inc. (JP) | 2004-10-13 | — | — | EP | claimed |
| US-9643976-B2 | Solvates of darunavir | AUROBINDO PHARMA LTD. (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| EP-2998291-A1 | A NOVEL PROCESS TO PREPARE INTERMEDIATES OF HIV-PROTEASE INHIBITORS THEREOF | ZCL Chemicals Ltd. (IN) | 2016-03-23 | — | — | EP | disclosed |
| US-20160075643-A1 | NOVEL PROCESS TO PREPARE INTERMEDIATES OF HIV-PROTEASE INHIBITORS THEREOF | ZCL CHEMICALS LIMITED (IN) | 2016-03-17 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-20150141382-A1 | NOVEL SOLVATES OF DARUNAVIR | AUROBINDO PHARMA LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| WO-2013108105-A2 | NOVEL SOLVATES OF DARUNAVIR | AUROBINDO PHARMA LIMITED (IN) | 2013-07-25 | — | — | WO | disclosed |
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5514801-A | TREATMENT OF AIDS | MONSANTO COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0677048-A1 | CYCLIC SULFONE CONTAINING RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0666842-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666843-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994014793-A1 | CYCLIC SULFONE CONTAINING RETROVIRAL PROTEASE INHIBITORS | G. D. SEARLE & CO. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994010136-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010133-A1 | SUCCINOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994010134-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | TRPM8 3829/4885CTRB1 304/4885SPPL2A 636/4885 |
| US-20150141382-A1 | NOVEL SOLVATES OF DARUNAVIR | DARS1, SAMHD1, SARS1 | TRPM8 4414/4885CTRB1 2647/4885SPPL2A 4249/4885 |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, DARS1, CYP3A43 | TRPM8 4647/4885CTRB1 2974/4885SPPL2A 4534/4885 |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | TRPM8 4500/4885CTRB1 3807/4885SPPL2A 4665/4885 |
| US-20050032889-A1 | Process for producing crystal of benzenesulfonamide derivative, and novel crystal of intermediate therefor and process for producing the same | WEE1, WEE2, NOTUM | TRPM8 3757/4885CTRB1 4306/4885SPPL2A 3302/4885 |
| US-20160075643-A1 | NOVEL PROCESS TO PREPARE INTERMEDIATES OF HIV-PROTEASE INHIBITORS THEREOF | PREP, PRSS1, DNPEP | TRPM8 3604/4885CTRB1 1236/4885SPPL2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.